Peptides Factory Direct See pricing & order
Home / Reference / FOXO4
Longevity / Mitochondrial - Research / formulation-specific

FOXO4 Research Reference

FOXO4-DRI is researched as a senolytic peptide concept intended to disrupt FOXO4-p53 interactions in senescent-cell models. Human use parameters and formulation standards are not established...

Research reference only. This is an educational, mechanism-level reference for an investigational research compound - not medical advice, a prescription, or a protocol to follow. Reconstitution, dosing, and pharmacokinetic figures are research-reference values for laboratory context only. Products are research-use-only, not for human or animal consumption, and not FDA approved. Confirm all concentration math and review with a qualified clinician before any formal research use.
See live pricing, stock & bundles for FOXO4

Create a free research account to view current pricing and place an order.

See live pricing & order →

Mechanism of action

FOXO4-DRI is researched as a senolytic peptide concept intended to disrupt FOXO4-p53 interactions in senescent-cell models. Human use parameters and formulation standards are not established.

Half-life & pharmacokinetics

Half-life: Not standardized.

Human PK is not standardized. This is a high-caution investigational senolytic concept rather than a routine peptide protocol.

Research dosing reference

0.5-2 mg intermittent research exposure; formal clinical dosing is not standardized.

Reconstitution & concentration

VialPreferred reconstitutionFinal concentration
10 mgDMSO or compatible solvent system may be required; verify formulationVariable

Injection timing

Intermittent use only in tightly structured research contexts.

Beginner escalation

Do not escalate casually; senolytic concepts require review-driven protocols.

Side-effect mitigation

Monitor systemic tolerance, inflammatory response, fatigue, and unexpected adverse effects.

Stack compatibility

Avoid stacking with other aggressive senolytic, immune-active, or mitochondrial stressors initially.

Storage & stability

Solvent choice is formulation-specific. Protect from heat/light; avoid assuming BAC compatibility.

Protocol duration & reassessment

High-caution investigational exposure only. Use short, tightly defined courses with extended reassessment intervals; do not repeat until tolerance, objective markers, and risk/benefit are reviewed. Bioregulators / Organ Support

Frequently asked questions

What is FOXO4 and how does it work?

FOXO4-DRI is researched as a senolytic peptide concept intended to disrupt FOXO4-p53 interactions in senescent-cell models. Human use parameters and formulation standards are not established.

What is the half-life of FOXO4?

FOXO4: Not standardized. Human PK is not standardized. This is a high-caution investigational senolytic concept rather than a routine peptide protocol.

How is FOXO4 reconstituted for research?

Preferred reconstitution for the 10 mg vial is DMSO or compatible solvent system may be required; verify formulation, giving Variable. Always confirm concentration math before any use. Research use only.

Is FOXO4 FDA approved?

No. FOXO4 is an investigational research-use-only compound - not for human or animal consumption and not FDA approved.

All research reference · Research guides

External references: Peptide (Wikipedia) · U.S. Food and Drug Administration

FOXO4 is an investigational research-use-only compound, not for human or animal consumption, not FDA approved, and not intended to diagnose, treat, cure, or prevent disease. This reference is not medical advice.